Navigation Links
Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Date:5/17/2011

WASHINGTON, May 17, 2011 /PRNewswire/ -- New data presented today show that RAPAFLO(R) (silodosin) significantly reduced symptoms of moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).  In the study presented at the annual meeting of the American Urological Association, RAPAFLO(R) also significantly improved urinary symptoms as well as quality of life.

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common condition characterized by persistent discomfort in the lower pelvic area and can have significant impact on quality of life. Symptoms can be severe and include painful and frequent urination and difficult or painful ejaculation. By definition, this type of prostatitis is not associated with a bacterial infection, and the cause is unknown. As many as 10 percent of men in North America have had or will have experienced prostatitis symptoms, and 90 percent of them have CP/CPPS. Evaluated in this trial for CP/CPPS, RAPAFLO(R) is a uniquely selective alpha blocker approved for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), commonly referred to as an enlarged prostate.

"In this well-controlled, double-blind study, RAPAFLO(R) has demonstrated significantly improved outcomes in men suffering from CP/CPPS," said J. Curtis Nickel, M.D., urologist at Kingston General Hospital and Professor of Urology at Queen's University in Kingston, Ontario, Canada, and lead author of the study. "Importantly, twice as many men treated with RAPAFLO 4 mg once daily versus placebo reported feeling a moderate to marked improvement in their condition, showing that the statistically significant findings also were clinically meaningful for the patients."

Study Results

In this Phase 2 study with 151 patients, compared with placebo, RAPAFLO(R) at a 4 mg dose significantly decreased the total score on the well-recognized National Institutes of Health Chronic Prostatitis Symptom Ind
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
3. Watsons GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
4. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
5. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
6. Vanda Pharmaceuticals Reports First Quarter 2011 Results
7. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
8. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... VetStem Biopharma, proudly announces former ... Schaffer, DVM, as Director of Veterinary Professional Services. ... experience in the veterinary regenerative medicine field Dr ... veterinarian lead organization”. Dr. Alexis Nahama, President ... be responsible for all technical activities in relationship ...
(Date:5/5/2015)... Israel , May 5, 2015  Tikcro ... Company was approved to continue trading on OTCQB  ... OTCQB Marketplace allows for a continuous ... broker-dealers. Investors can have real-time quotes and market ... The OTCQB Marketplace includes U.S. and ...
(Date:5/5/2015)... YORK , May 5, 2015 ... announced that Andrew Gengos , President and Chief ... May 7, 2015. DATE:  Thursday, May 7, ... LINK:  http://VirtualInvestorConferences.com > click the red ... be a live, interactive online event where investors ...
(Date:5/5/2015)... , May 05, 2015 Research and Markets ... addition of the "Clinical Laboratory, Molecular Diagnostics ... 2015 to 2019 - Global Version" report ... especially in the area of molecular diagnostics and ... and evolving world market that is moving out ...
Breaking Biology Technology:Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... have made a breakthrough toward creating nanocircuitry on graphene, ... silicon as the building block of transistors. They have ... thermochemical nanolithography (TCNL) for creating nanowires, tuning the electronic ... thereby allowing it to switch from being an insulating ...
... oxide, a single-atomic-layered material made by reacting graphite powders ... interest from scientists because of its ability to easily ... scientists believe could be used to produce low-cost carbon-based ... assistant professor of materials science and engineering, and his ...
... Germany and LAUSANNE, Switzerland and ... Medicines Initiative for,Diabetes"), a public private consortium funded by ... a project focusing on,pancreatic islet cell function and survival. ... biomarkers and tools to pave the way,for improved disease ...
Cached Biology Technology:Scientists strive to replace silicon with graphene on nanocircuitry 2Scientists strive to replace silicon with graphene on nanocircuitry 3Researchers discover new properties of World's thinnest material 2Launch of IMIDIA - An Innovative Medicines Initiative Project for Diabetes 2Launch of IMIDIA - An Innovative Medicines Initiative Project for Diabetes 3Launch of IMIDIA - An Innovative Medicines Initiative Project for Diabetes 4
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced ... Strategic Business Report" report to their offering. This ... US$ Thousands by the following Segments: Face Biometrics, and Voice Biometrics. ... Canada , Japan , Europe ... & Africa , and ...
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... Salmonella have a complicated immune system that helps them ... cell membrane, according to a University of Washington-led study ... research, which also included scientists at the Sidney Kimmel ... for understanding the evolution of disease-causing bacteria. The findings ...
... who are extremely obese may be underestimated as a new ... and high cholesterol than women at lower levels of obesity, ... JAMA. , Obesity diagnosis and treatment are typically based on ... calculated as weight in kilograms divided by height in meters ...
... results, researchers have shown that a drug which mimics the ... develop in the part of the brain where cells are ... long-lasting recovery of function in an animal model of PD. ... PD and other neurodegenerative diseases. The study was funded ...
Cached Biology News:Bacteria have their own immune system protecting against outside DNA 2Higher levels of obesity associated with greater health risks 2Higher levels of obesity associated with greater health risks 3Dopamine drug leads to new neurons and recovery of function in rat model of Parkinson's 2Dopamine drug leads to new neurons and recovery of function in rat model of Parkinson's 3
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Goat polyclonal to DRAK2...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
... CDX2, a member of the caudal-related homeobox ... regulates both proliferation and differentiation in intestinal ... in triggering cells towards the phenotype of ... the maintenance of the phenotype. Clone CDX2-88 ...
Biology Products: